ADENO-ASSOCIATED VIRUS SEROTYPE I NUCLEIC ACID SEQUENCES, VECTORS AND HOST CELLS CONTAINING SAME
The nucleic acid sequences of adeno-associated virus (AAV) serotype 1 are provided, as are vectors and host cells containing these sequences and functional fragments thereof. Also provided are methods of delivering genes via AAV-1 derived vectors.
1 . (canceled)
2 . A composition comprising 1×10 9 to 1×10 16 genomes of a recombinant adenovirus having an AAV1 capsid comprising a vp1 protein, a vp2 protein, and a vp3 protein, wherein said vp3 protein has an amino acid sequence of SEQ ID NO:17, wherein said recombinant virus further comprises a heterologous molecule which comprises an AAV 5′ inverted terminal repeat sequence (ITR), a transgene, and an AAV 3′ ITR, and a pharmaceutically acceptable carrier.
3 . The composition according to claim 2 , comprising 1×10 13 to 1×10 16 genomes.
4 . The composition according to claim 1 , wherein said vp1 protein has the amino acid sequence of SEQ ID NO: 13.
5 . The composition according to claim 1 , wherein said vp2 protein has the amino acid sequence of SEQ ID NO: 15.
6 . The composition according to claim 1 , wherein the 5′ ITR and 3′ ITR are of AAV serotype 2.
7 . The composition according to claim 1 , further comprising a promoter which directs expression of the transgene.
8 . The composition according to claim 1 , wherein said transgene encodes a protein or peptide.
9 . The composition according to claim 8 , wherein said protein or peptide is a therapeutic protein or peptide.
10 . The composition according to claim 8 , wherein said protein or peptide is an immunogenic protein or peptide.
11 . The composition according to claim 1 , wherein said transgene encodes a cytokine, a hormone, or a growth factor.
12 . The composition according to claim 1 , wherein said composition is formulated for delivery to muscle.
13 . The composition according to claim 7 , wherein the promoter is a cytomegalovirus promoter.